Observational Retrospective Study of the Treatment of Waldenström's Macroglobulinemia with Ibrutinib in Routine Clinical Practice in Spain
Overall response rate was 92.2%, with a major response rate of 80.5%.
Waldenström’s macroglobulinemia is a B‑cell neoplasia characterized by a lymphoplasmacytic lymphoma in the bone marrow and abnormal secretion of IgM paraprotein. Although clinical trials have demonstrated high efficacy of the Bruton tyrosine kinase inhibitor ibrutinib, real‑world data on its effectiveness and safety in routine practice remain limited. The MACRO study assessed the clinical, genetic, and demographic characteristics of patients with symptomatic Waldenström’s macroglobulinemia treated with ibrutinib in Spain and reported on response rates, progression‑free survival, overall survival, and safety. The results confirm ibrutinib’s high effectiveness and manageable safety profile in a real‑world setting.
This sentence directly reports the efficacy outcomes of the real‑world study, which are the primary endpoints of the research.
Bizonyítékszint: Állatkísérletes. Állatmodellben vizsgálták.
Kapcsolódó jelek
- Multiple Myeloma Clinical Trials & Emerging Therapies
- A single‑cell atlas of multiple myeloma defines malignant archetypes and proliferative states
- S2209: Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM)
- Improved survival in multiple myeloma following prior detection of precursor conditions: a nationwide real-world study
- Nanomedicine-Empowered CAR‑T Therapy for Multiple Myeloma: Toward Programmable, Durable, and Precision Immunotherapy